The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
Location contact
Guifang Xu
CONTACT
NCT Number: NCT07744646
The purpose of this protocol is to evaluate the safety and efficacy of Alpha-0261 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that Alpha-0261 is safe, and the secondary hypothesis is that Alpha-0261 is effective, as assessed by the proportion of participants achieving clinical remission per the complete modified Mayo score at Week 10.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Phase 1
Hefei, Anhui, 230000, China
Guifang Xu
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drug: Alpha-0261 Oral, tablet
Time frame: From enrollment to the end of study at 12 weeks.
Safety endpoints: These include, but are not limited to, adverse events (AEs) and serious adverse events (SAEs), vital signs, physical examinations, 12-lead electrocardiograms (ECGs), and clinical laboratory tests (complete blood count, urinalysis, blood chemistry, and coagulation tests).
Time frame: From enrollment to the end of treatment at 10 weeks.
Percentage of participants with clinical remission at Week 10 (complete modified Mayo score: stool frequency ≤1, rectal bleeding =0, and site-read endoscopy subscore ≤1).
Contact information is provided by the study sponsor or research team.
The First Affiliated Hospital of Anhui Medical University
Other
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Alpha-0261 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis (UC)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07747155
Colitis, Colitis, Ulcerative
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07749768
Colitis, Colitis, Ulcerative
Miami, Florida, United States
View Trial DetailsNCT07686757
Colitis, Colitis, Ulcerative
Sun City, Arizona, United States
View Trial DetailsNCT07742410
Colitis, Colitis, Ulcerative
View Trial Details